A combination of methylprednisolone and prednisolone and a combination of Methylprednisolone, prednisolone and mizoribine for systemic lupus erythematosus in children: A randomized controlled trial of efficacy and safety izolibin for (JSRDC04)
Not Applicable
- Conditions
- systematic lupus erythematosus
- Registration Number
- JPRN-C000000378
- Lead Sponsor
- Japanese Study Group of Renal Disease in Children(JSRDC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1.Chronic rheumatoid arthritis, diffuse scleroderma or dermatomyositis. 2.History of immunosuppressive drugs administration. 3.Medical history of allergy or hypersensitivity reactions to mizoribine. 4.Poorly controlled hypertension. 5.Active infectious disease. 6.Severe liver disfunction. 7.Pregnancy. 8.Judged inappropriate for this study by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative flare rate
- Secondary Outcome Measures
Name Time Method